News
-
-
PRESS RELEASE
Trans Canada Gold Corp. Ships 3,919 Barrels for the Month of April 2025, From its Lloydminster Multilateral Heavy Oil Well and Prepares for the Summer Mulitlateral Drilling Program
Trans Canada Gold Corp announces completion of another month of steady oil production for April 2025 and plans to commence drilling a multi-lateral well targeting Sparky formation in summer 2025 -
-
-
-
-
PRESS RELEASE
Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback
Tharimmune, Inc. presents promising pharmacokinetic and metabolism data of TH104, a buccal film of nalmefene, for prophylaxis against opioid exposure. Study results showcased at Digestive Disease Week 2025 -
PRESS RELEASE
Galimedix Therapeutics completes single ascending dose part of Phase 1 study with oral small molecule, GAL-101, an amyloid beta aggregation modulator
Galimedix Therapeutics completes single ascending dose of Phase 1 study with oral small molecule GAL-101 targeting amyloid beta aggregation modulator, supporting oral administration route. Next study arms and indications revealed -
-
PRESS RELEASE
MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity
MIRA Pharmaceuticals announces positive preclinical results for oral NMDA receptor antagonist Ketamir-2, showing no brain toxicity. Phase I clinical trial ongoing
